Loading clinical trials...

Study of the Immune Response in Colon Adenocarcinoma | Clinical Trials | Clareo Health

COMPLETED

Study of the Immune Response in Colon Adenocarcinoma

Etude de la réponse Immunitaire Dans l'adénocarcinome Colique

NCT03015038•Institut National de la Santé Et de la Recherche Médicale, France

Summary

Duration of each part of the study per patient: * Screening: From 1 to 4 weeks * Sampling period (blood and tissue): 1 day * Follow-up by patient: 60 months * Total study duration by patient: 84 months * Total inclusion duration: 24 months * Total Follow-up duration: 60 months * Total study duration: 84 months

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•1. Patients aged 18 or more.
•2. Affiliation to a social security scheme
•3. Diagnosis of a colon adenocarcinoma.
•4. Patient have signed and dated consent of the study before undertaking procedures related to the study.

Exclusion Criteria

•1. Patients under guardianship / curatorship
•2. Following Situations
•* Persons unable to understand, read and / or sign an informed consent
•* Patient with the following functions: investigator or co-investigator, research assistant, pharmacist, study coordinator or having any involvement in the study
•* Uncooperative person or potentially non-compliant for the study and its procedures with predictable difficulties regular monitoring of over 1 year.
•* No affiliation to a social security scheme, a universal medical coverage or any similar plan.
•3. Pregnant or lactating women.
•4. Patients with HIV seropositivity.
•5. Rectal tumor location.

Locations (1)

Hôpital Saint Louis

Paris, France

Key Dates

Start Date

February 5, 2017

Primary Completion Date

February 5, 2024

Completion Date

February 5, 2024

Last Updated

December 10, 2025

Enrollment

100

ACTUAL participants

Conditions

Colon Adenocarcinoma

Inhalational or Intravenous Anesthesia During Surgery for Patients With Colon Cancer, VIVA Study

NCT06017141

Colon Adenocarcinoma

View study

ACTIVE_NOT_RECRUITINGPHASE2

Study of Cabozantinib and Nivolumab in Refractory Metastatic Microsatellite Stable (MSS) Colorectal Cancer

NCT04963283

Colorectal AdenocarcinomaColon Cancer+5 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: December 10, 2025Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Study of the Immune Response in Colon Adenocarcinoma

Inclusion Criteria

Exclusion Criteria

Inhalational or Intravenous Anesthesia During Surgery for Patients With Colon Cancer, VIVA Study

Study of Cabozantinib and Nivolumab in Refractory Metastatic Microsatellite Stable (MSS) Colorectal Cancer

Young-Onset Colorectal Cancer

Circulating Tumor DNA Testing in Predicting Treatment for Patients With Stage IIA Colon Cancer After Surgery

Panitumumab, Regorafenib, or TAS-102, in Treating Patients With Metastatic and/or Unresectable RAS Wild-Type Colorectal Cancer

TAS-102, Irinotecan, and Bevacizumab for the Treatment of Pre-treated Metastatic or Unresectable Colorectal Cancer, the TABAsCO Study